Medefil Heparin I.V. Flush Syringe 10 units/mL; a polypropylene luer locking syringe containing Heparin Lock Flush Solution, USP, a sterile non-pyrogenic, isotonic injection; each mL in a Heparin I.V. Flush Syringe contains 10 units of heparin sodium derived from porcine intestinal mucosa and 9 mg of sodium chloride in water for injection; Medefil, Inc., Glendale Heights, IL 60139 The pre-filled syringes were packed 60 syringes per dispenser box, 16 boxes per shipping carton in the following syringe configurations: a) NDC #64253-222-35, catalog #MIH-2235: 5 mL fill in 12 mL syringe b) NDC #64253-222-33, catalog #MIH-2233: 3 mL fill in 12 mL syringe
This recall has been terminated (originally issued May 9, 2008).
- Company
- Medefil Incorporated
- Recall Initiated
- March 20, 2008
- Posted
- May 9, 2008
- Terminated
- April 15, 2010
- Recall Number
- Z-1544-2008
- Quantity
- 453,300 syringes
- Firm Location
- Glendale Heights, IL
- Official Source
- View on FDA website ↗
Reason for Recall
The heparin lock flush solution was manufactured from contaminated Heparin Sodium USP Active Pharmaceutical Ingredient (API). The FDA has received reports of serious injuries and/or deaths in patients administered finished heparin injectable products manufactured from heparin API containing this contaminant.
Distribution
Class II Recall - Nationwide Distribution --- including states of Arizona, Florida, Illinois, Massachusetts, Pennsylvania, and Texas.
Lot / Code Info
catalog #MIH-2235: lot H07325, exp. date 11/09, H08113, exp. date 12/09; catalog #MIH-2233: lot H08124, exp. date 01/10
Root Cause
Material/Component Contamination
Action Taken
Medefil telephoned the direct accounts on 3/20/08, e-mailed them a copy of the 3/20/08 recall letter on 3/21/08, and sent the accounts a hard copy of the recall letter on 3/24/08. The accounts were informed of Medefil's recall of 19 lots of Heparin I.V. Flush Syringes produced from the active pharmaceutical ingredient (API) Heparin Sodium, USP, lot 1035-0773, that has been recalled by the manufacturer, Scientific Protein Laboratories, due to the presence of a contaminant in the recalled lot of API. The accounts were instructed to stop use of the 19 lots of Heparin I.V. Flush Syringes immediately, place them under quarantine, and contact all customers to whom they further distributed the product, telling them to stop use of the product and return the product to Medefil through their supplier. The accounts were requested to complete and return to Medefil via fax the enclosed response form, indicating the quantity on hand of each recalled lot. Any questions were directed to Pradeep Aggarwal, President at 630-682-4600.